본문으로 건너뛰기
← 뒤로

Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial.

2/5 보강
Journal of hepato-biliary-pancreatic sciences 📖 저널 OA 40.9% 2024: 3/9 OA 2025: 9/17 OA 2026: 6/18 OA 2024~2026 2026 Pancreatic and Hepatic Oncology Rese
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
187 patients were classified according to the interval between surgery and chemotherapy initiation to Early (< 6 weeks, n = 45), Standard (6-8 weeks, n = 70), and Delayed (> 8 weeks, n = 72).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Multivariate analysis identified operative procedure, R1 resection, lymph node metastasis, and nonstandard initiation (< 6 or > 8 weeks) as independent adverse prognostic factors. [CONCLUSIONS] Initiation of S-1 AC at 6-8 weeks after pancreatectomy was associated with favorable survival outcomes.
OpenAlex 토픽 · Pancreatic and Hepatic Oncology Research Lung Cancer Diagnosis and Treatment Cholangiocarcinoma and Gallbladder Cancer Studies

Lee D, Okamura Y, Nanno Y, Mizumoto T, Ishida J, Gotohda N

📝 환자 설명용 한 줄

[BACKGROUND] Relationship between timing of initiating adjuvant chemotherapy (AC) and clinical outcomes after surgery for pancreatic cancer remains controversial.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 45
  • p-value p = 0.041
  • p-value p = 0.077
  • 95% CI 0.38-0.99

이 논문을 인용하기

↓ .bib ↓ .ris
APA Dongha Lee, Yukiyasu Okamura, et al. (2026). Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial.. Journal of hepato-biliary-pancreatic sciences. https://doi.org/10.1002/jhbp.70117
MLA Dongha Lee, et al.. "Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial.." Journal of hepato-biliary-pancreatic sciences, 2026.
PMID 41999030 ↗
DOI 10.1002/jhbp.70117

Abstract

[BACKGROUND] Relationship between timing of initiating adjuvant chemotherapy (AC) and clinical outcomes after surgery for pancreatic cancer remains controversial.

[METHODS] In this ancillary analysis of the JASPAC 01 trial, 187 patients were classified according to the interval between surgery and chemotherapy initiation to Early (< 6 weeks, n = 45), Standard (6-8 weeks, n = 70), and Delayed (> 8 weeks, n = 72). Overall survival (OS) and relapse-free survival (RFS) were analyzed.

[RESULTS] Baseline characteristics were comparable among three groups. The Standard group showed significantly longer OS than the Early group (median, 66 vs. 37 months; HR 0.61, 95% CI 0.38-0.99; p = 0.041), and relatively longer OS compared with the Delayed group (median, 45 months; HR 0.68, 95% CI 0.44-1.05; p = 0.077). RFS was longer in the Standard group (median, 46 months) compared with the Early group (20 months; HR 0.61, 95% CI 0.38-0.99; p = 0.040) and the Delayed group (20 months; HR 0.59, 95% CI 0.39-0.89; p = 0.011). Multivariate analysis identified operative procedure, R1 resection, lymph node metastasis, and nonstandard initiation (< 6 or > 8 weeks) as independent adverse prognostic factors.

[CONCLUSIONS] Initiation of S-1 AC at 6-8 weeks after pancreatectomy was associated with favorable survival outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반